Platinex Announces New Website is Live

TORONTO, ONTARIO–(Marketwired – March 30, 2017) – Platinex Inc. (CSE:PTX)(CSE:PTX.CN) („Platinex” or the „Company„) has launched its new website. Additional content will be entered progressively.

The websites for the new online cannabis shopping mall venture are under construction. The URLs are CannabisMall.shop and CannabisMall.org.

About Platinex Inc.

Platinex’s goal is to create shareholder value through entrepreneurial endeavors and its existing mineral exploration activities. The mining focus is currently on the Shining Tree gold camp, which has received little modern exploration compared to other gold camps in the Abitibi Greenstone Belt, but its potential is accentuated by several major discoveries along strike in recent years. Its current entrepreneurial activities include the establishment of a cannabis mall. Shares of Platinex are listed for trading on the Canadian Securities Exchange („CSE”) under the symbol „PTX”.

To receive Company press releases, please email jtrusler@platinex.com and
mention „Platinex press release” on the subject line.

FORWARD-LOOKING STATEMENTS:

Certain of the information contained in this news release may contain „forward-looking information”. Forward-looking information and statements may include, among others, statements regarding the future plans, costs, objectives or performance of Platinex, or the assumptions underlying any of the foregoing. In this news release, words such as „may”, „would”, „could”, „will”, „likely”, „believe”, „expect”, „anticipate”, „intend”, „plan”, „estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company’s control. The Company does not intend, nor does the Company undertake any obligation, to update or revise any forward-looking information or statements contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

INTUNIV(R) (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan

ZUG, Switzerland, March 30, 2017 /PRNewswire/ —

A New Non-stimulant Clinical Option for Children and Adolescents From 6 to 17 Years old With ADHD 

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that its partner in Japan, Shionogi & Co., Ltd, has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market INTUNIV. INTUNIV is a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD),[1] a common psychiatric disorder in children and adolescents.[2],[3]

ADHD causes inattention, hyperactivity or impulsivity, or a combination of these symptoms,[4],[5] and can have substantial impact on all major areas of life, including: schooling, work and employment, behaviour, social functioning, self-esteem and health.[6][9]

INTUNIV is a selective alpha-2A adrenergic receptor agonist.[1] With a unique mechanism of action, INTUNIV represents an additional treatment option in the management of ADHD.

“Shire is committed to ensuring that every person with ADHD is able to benefit from a treatment most suited to their needs,” said Philip J Vickers, PhD, Global Head of Shire Research and Development. “The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Japan, who may benefit from a new treatment option.”

As part of the partnership, a Phase 3 placebo-controlled clinical study and long-term extension study evaluating the efficacy and safety of INTUNIV in 254 patients was conducted in Japan. In the trial, INTUNIV administered once daily, showed significant improvements over placebo, as measured by ADHD-RS-IV total score, in all core symptoms of ADHD: hyperactivity/impulsivity, and inattention. The most common adverse events were somnolence in 146 patients (57.5%), decreased blood pressure in 39 patients (15.4%), and headache in 31 patients (12.2%).[1]

ADHD is a complex condition and approaches to treatment typically include educational methods, psychotherapy and medication.[10] When required, either stimulants or non-stimulants are indicated as part of a comprehensive treatment programme for ADHD. Children and adolescents have a wide spectrum of individual needs as patients, so it is important that a range of treatment options are available. Non-stimulant medications are an important alternative to stimulants for some ADHD patients.[10]

About ADHD 

Attention deficit hyperactivity disorder (ADHD) is recognised by the World Health Organization (WHO).[2] Worldwide prevalence of ADHD is estimated to vary between 5.9% and 7.1%.[3]

Whilst the exact origin of ADHD is not fully understood, the area of the brain known as the prefrontal cortex is known to control several cognitive functions including attention and social behaviours,[9],[ 11],[12] and has been associated with some structural and functional abnormalities in individuals with ADHD.[13][15]

About INTUNIV 

INTUNIV (guanfacine hydrochloride prolonged release) is a once-daily non-stimulant indicated for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents from 6 to 17 years old.[1]

INTUNIV provides significantly improved ADHD symptom control vs. placebo[1],[16] and has a well-documented safety profile across the dose range.[1]

INTUNIV contains the active substance guanfacine, a selective alpha-2A adrenergic receptor agonist.[1] Studies suggest that guanfacine may exert physiological effects by selectively stimulating the alpha-2A adrenergic receptor in the prefrontal cortex.[17][18]

INTUNIV is currently approved by Shire in the US, Canada, and Europe. Please refer to the local label for the approved indication.

INTUNIV Safety Information for Japan[1]

Precautions on indication 

  1. The efficacy and safety of INTUNIV in children under 6 years of age or adults over 18 years of age have not been established.
  2. If INTUNIV is continued after age 18 in patients who started pharmacological treatment with this drug before the age of 18 years, it should be administered with caution after the therapeutic benefits are weighed against the possible risks. The efficacy and safety of INTUNIV should regularly be evaluated, and if INTUNIV is of no value, it should be considered for discontinuation and must not be administered without purpose.
  3. A diagnosis of ADHD must be made with caution, according to standard, established diagnostic criteria, including DSM* published by the American Psychiatric Association. INTUNIV must be used only in patients who meet such criteria.

*Diagnostic and Statistical Manual of Mental Disorders

Contraindication (INTUNIV is contraindicated in the following patients.) 

  1. Patients with a history of hypersensitivity to any of the ingredients of this drug.
  2. Pregnant women or women who may possibly be pregnant.
  3. Patients with atrioventricular block second-degree and third-degree. [The condition may get worse because of the central bradycardia effect of this drug.]

Precautions 

1. Careful Administration (INTUNIV should be administered with care in the following patients.) 

  1. Patients with a current or previous history of hypotension, orthostatic hypotension, bradycardia, or cardiovascular disease, or patients treating with drugs which can reduce blood pressure or pulse rate [INTUNIV may decrease blood pressure and heart rate.]
  2. Patients with a current or previous history of hypertension [Blood pressure may increase when administration of this drug is abruptly discontinued.]
  3. Patients with a current or previous history of arrhythmia, patients with congenital long QT syndrome or patients treating with drugs that are known to cause QT prolongation [QT prolongation may occur because of this drug.]
  4. Patients with a current or previous history of ischaemic heart disease such as angina pectoris and myocardial infarction [If the acute reduction of blood pressure occurs, ischaemic heart disease may get worse because of the decreased coronary flow.]
  5. Patients with cerebrovascular disorder such as cerebral infarction etc. [If the acute reduction of blood pressure occurs, the symptoms may be aggravated due to the decrease in cerebral blood flow.]
  6. Patients with severe hepatic function disorder [The blood concentration of this drug may increase.]
  7. Patients with severe renal function disorder [The blood concentration of this drug may increase.]
  8. Patients in depressed state [The symptom may get worse because of the sedative effects of this drug.]

2. Important precautions 

  1.  Before prescribing INTUNIV, the physician or healthcare professional should fully inform the patient and his/her parent or other appropriate representative of its therapeutic position and potential risks, including adverse reactions to the drug, and instruct the patient on the proper administration method.  
  2.  During long-term use of INTUNIV, the value of ongoing treatment should be periodically assessed and patients should not be administered without purpose. ~ 
  3.  Since syncope may occur when advanced decreases in blood pressure or pulse rate are observed, blood pressure and pulse rate should be measured prior to initiation of treatment of INTUNIV and 1-2 weeks after changing the dosage. Blood pressure and pulse rate should also be measured at intervals of once in 4 weeks after setting an optimal dose. Also, dehydration along with the administration of INTUNIV should be fully cautioned. If any dehydration symptoms are observed, proper care such as fluid replacement should be taken.  
  4.  Since the effects on cardiovascular system (advanced bradycardia, hypotension, QT prolongation etc.) may appear, the following points should be cautioned before and during treatment with INTUNIV.

     i)  The presence or absence of abnormality in ECG should be confirmed before treatment with INTUNIV. If any abnormality in ECG is observed, the initiation of administration should be carefully judged.
     ii) When INTUNIV is administered to patients with cardiovascular disease or with a medical history of cardiovascular disease, or any abnormality in ECG is observed before treatment with INTUNIV, patients’ condition should be carefully observed by conducting routine ECG and so on.
     iii) Patients’ cardiovascular condition should be cautioned during treatment with INTUNIV. If any symptoms suggesting the effects on cardiovascular system (bradycardia, syncope, dizziness, palpitations, etc.) appear, proper care should be taken by conducting ECG and so on.

  5. Since suicidal ideation or behavior may occur, patient’s condition should be carefully observed. Also, patients, the parents or other appropriate representative should be instructed to contact a medical institution immediately, if any suicidal symptoms occur.
  6. While hostility and aggression are frequently observed in AD/HD patients, occurrence of these events during treatment has been also reported. The occurrence or worsening of these events should be carefully monitored during treatment.
  7.  Since INTUNIV may cause weight increase, body weight should be monitored regularly. If any symptom of obesity appears, proper care should be taken such as food therapy, movement therapy, etc.
  8.  Since sleepiness, sedation, etc. may occur, patients should be cautioned not to engage in operating potentially hazardous machinery, including automobiles during treatment.

Drug interactions 

This drug is primarily metabolized by the hepatic metabolizing enzymes CYP3A4 and CYP3A5.

Adverse reactions 

Out of 254 patients evaluated for safety before NDA approval, adverse reactions (including abnormal changes in laboratory values) were observed in 190 patients (74.8%). Main adverse reactions were somnolence in 146 patients (57.5%), decreased blood pressure in 39 patients (15.4%), and headache in 31 patients (12.2%).

1. Clinically significant adverse reactions 

  1. Hypotension (5%), bradycardia (5%): Since advanced hypotension or/and bradycardia may occur and lead to syncope, patients’ condition should be carefully monitored, measuring blood pressure and pulse rate regularly. If any of these symptoms appears, proper care such as dose reduction, interruption, or discontinuation should be taken.
  2. Syncope (Incidence unknown[Note 1]): Since syncope may occur, patients should be fully observed. If any abnormality is observed, proper care such as discontinuation of administration should be taken.
  3. Atrioventricular block (<0.5%): Since atrioventricular block may occur, proper care such as dose reduction, interruption, or discontinuation should be taken if any abnormality is observed.

2. Other adverse reactions 

If the following adverse reactions occur, appropriate measures such as dose reduction, interruption, or discontinuation should be taken as necessary.


   
                     greater than   <5%, greater
                         or equal        than or                     Incidence
     Type/ Incidence        to 5%    equal to 1%      <1%           unknown[Note 1]

                                                                     Hypersensitivity,
    Hypersensitivity                                                 rash, pruritus

 
                                                                     Tachycardia, sinus
                                                                     arrhythmia, pallor,
                                     Orthostatic   Increased         hypertensive
      Cardiovascular                 hypotension   blood pressure    encephalopathy
  
                                                   Nightmare,
                                                   affect
                      Somnolence,                  lability,
                        headache,                  agitation,        Anxiety, depression,
                        insomnia,                  sedation,         lethargy, convulsion,
    Psychoneurologic    dizziness   Irritability   asthenia          hypersomnia
 
                                     Decreased
                                     appetite,
                                       nausea,
                                    constipation,
                                      diarrhea,
                        Abdominal      thirst,                       Abdominal discomfort,
    Gastrointestinal         pain     vomiting                       dyspepsia

                                     Enuresis,    Pollakiuria,
                                     increased    increased ALT      Asthma, chest pain,
    Others               Malaise       weight     (GPT)              dehydration

Note 1: The incidence of adverse reactions on the basis of overseas clinical studies and spontaneous reports is unknown.

NOTES TO EDITORS 

About Shire 

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work everyday with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

http://www.shire.com

Forward-Looking Statements 

Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:

  • Shire’s products may not be a commercial success;
  • increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire’s future revenues, financial condition and results of operations;
  • Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
  • the manufacture of Shire’s products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • certain of Shire’s therapies involve lengthy and complex processes, which may prevent Shire from timely responding to market forces and effectively managing its production capacity;
  • Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
  • the actions of certain customers could affect Shire’s ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire’s revenues, financial conditions or results of operations;
  • Shire’s products and product candidates face substantial competition in the product markets in which it operates, including competition from generics;
  • adverse outcomes in legal matters, tax audits and other disputes, including Shire’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the Company’s revenues, financial condition or results of operations;
  • inability to successfully compete for highly qualified personnel from other companies and organizations;
  • failure to achieve the strategic objectives, including expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all with respect to Shire’s acquisitions, including NPS Pharmaceuticals Inc., Dyax Corp. or Baxalta Incorporated may adversely affect Shire’s financial condition and results of operations;
  • Shire’s growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products;
  • a slowdown of global economic growth, or economic instability of countries in which Shire does business, as well as changes in foreign currency exchange rates and interest rates, that adversely impact the availability and cost of credit and customer purchasing and payment patterns, including the collectability of customer accounts receivable;
  • failure of a marketed product to work effectively or if such a product is the cause of adverse side effects could result in damage to Shire’s reputation, the withdrawal of the product and legal action against Shire;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
  • Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
  • Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which may decrease its business flexibility and increase borrowing costs; and

A further list and description of risks, uncertainties and other matters can be found in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in “ITEM 1A: Risk Factors”, and in Shire’s subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire’s website.

All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

References 

  1. INTUNIV Prescribing Information, Shionogi & Co., Ltd 2017.
  2. POLANCZYK, G. et al. (2007). The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. Am J Psych. 164:942-948.
  3. WILLCUTT, EG. (2012). The Prevalence of DSM-IV Attention-deficit/Hyperactivity Disorder: A Meta-analytic Review. Neurotherapeutics. 9:490-499.
  4. International Classification of Diseases, 10th ed., (ICD-10). World Health Organization 2007. Chapter 5,F90. http://apps.who.int/classifications/icd10/browse/2010/en#/F90-F98. Last accessed June 2014.
  5. American Psychiatric Association. (2013) Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). Arlington, VA: American Psychiatric Publishing.
  6. DIAMANTOPOULOU S, et al. Impact of Executive Functioning and Symptoms of Attention Deficit Hyperactivity Disorder on Children’s Peer Relations and School Performance. Dev Neuropsychol 2007; 32(1):521-542.
  7. BIEDERMAN J, et al. Functional Impairments in Adults with Self-reports of Diagnosed ADHD: A Controlled Study of 1001 Adults in the Community. J Clin Psychiatry 2006; 67:524-540.
  8. SHAW M, et al. A Systematic Review and Analysis of Long-term Outcomes in Attention Deficit Hyperactivity Disorder: Effects of Treatment and Non-treatment. BMC Medicine 2012; 10:99.
  9. MANES, F. et al. (2002). Decision-making processes following damage to the prefrontal cortex. Brain. 125:624-639.
  10. TAYLOR, E. et al. (2004). European clinical guidelines for hyperkinetic disorder – first upgrade. European Child and Adolescent Psychiatry. 13 Suppl 1:i7-i30.
  11. WILKINS, AJ. et al. (1987). Frontal lesions and sustained attention. Neuropsychologia. 25:359-365.
  12. ANDERSON, SW. et al. (1999). Impairment of social and moral behavior related to early damage in human prefrontal 
cortex. Nature Neuroscience. 2:1032-1037.
  13. FARAONE S, et al. (2005) Molecular Genetics of Attention Deficit Hyperactivity Disorder. BioPsych 57:1313-1323.
  14. RUBIA, K. et al. (1999). Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. American Journal of Psychiatry. 156:891-896.
  15. HOEKZEMA, E. et al. (2014). An independent components and functional connectivity analysis of resting state FMRI data points to neural network dysregulation in adult ADHD. Human Brain Mapping. 35:1261-1272.
  16. HERVAS, A. et al. (2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and
adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial. European Neuropsychopharmacology. 24:1861-1872.
  17. REN, WW. et al. (2012). Stimulation of α(2A)-adrenoceptors promotes the maturation of dendritic spines in cultured neurons of the medial prefrontal cortex. Molecular and Cellular Neuroscience. 49:205-216.
  18. WANG, M. et al. (2007). Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN 
channel signaling in prefrontal cortex. Cell 129:397-410.

For further information please contact:
Media
Lauren Starr
lauren.starr@shire.com
+41-41-288-4443

My Virgin Diary: Life Takes a ‘U-Turn’ at the Hostel

NEW DELHI, March 30, 2017 /PRNewswire/ —

– ‘My Virgin Diary’ Movie, Reveals and Relives the North Campus Hostel Life – Nalin Singh

Brought to you by NRAI Productions

Those midnight discussions, sharing’s of almost everything possible, code words, mental outbursts and of course the unconditional support of hostellers, indeed, hostel life is full of shades and hues. That’s the reason why hostel life is considered as the best part of one’s life.

Delhi’s North Campus life has always been a thing of curiosity for the distant spectators. The legends of North Campus hostel life have been amusing generations since long. Actor-director Nalin Singh is bringing this forbidden fruit, to the audience, in the form of his out-of-the-box movie ‘My Virgin Diary which is going to be released on all the major international and national digital platforms.

The thrill of the real hostel life is somewhat beyond verbal descriptions. Nalin Singh has portrayed life in a hostel with all its bare and bitter truths. Nalin, a Hindu College pass-out and a former GTB Nagar – Kingsway Camp hostel dweller, has brought this unadulterated hostel saga to make the viewers to retrospect and introspect at a time.

“We used to have a special lingo which only we could decode. We nicknamed almost every single creature in our hostel including the gatekeeper,” reminisces Nalin. “Unlike portrayed in many Bollywood movies, including an epoch making movie ‘Three Idiots’ which is more of fun, the real hostel life has many dark shades. We were four roommates. Everyone was from a different background, everyone had their fortunes and misfortunes, but everyone had a story,” said Nalin, while revealing his ambitious upcoming celluloid project ‘My Virgin Diary‘, which is an ensemble of stories from Delhi’s North Campus hostel life. “One of my roommates had committed suicide and in this movie, I’ve tried to ascertain as to what influenced his mind.”

Praying at the virgin tree, to get rid of virginity, eying on friend’s girlfriend’s friend, forming a musical band, doing plays, beginning and ending every celebration with GPL, busting any kind of stress by’ Chai-Sutta’, applying engineering, mechanism and creativity for some bizarre Jugaads, weeping uncontrollably for some deep hidden grieves, all make hostel life an inspiring part of your life. And by the time you leave the hostel, you are ready to enter the Big Bad World!” said Nalin, nostalgically.

Image Link of Nalin Singh

https://scontent.fdel1-1.fna.fbcdn.net/v/t1.0-9/12801251_1741162372773219_2336039821762610998_n.jpg?oh=4d13dfaed6a581f58e8c22c46f28bb60&oe=595D55E9

Credits

Director: Nalin Singh

Editor: Mahipal Singh

Music Director: Mukesh Rajeshwari Singh

Script: Arunesh Ranjan, Nalin Singh

Lyrics: Rohit Raj

Cast: Mohit Tiwari, Julia Steffany, Rakesh Chaudhary, Barbara Campagna, Aneerudh Ganguly, Kritika Tanna, Ramesh Kundu, Agastya Arunachal, Hirdey Singh, Anuraag Awasthi, Kundan

Asst. Director: Sharon Bora (Chief), Mohit Anand, Ajay Dhar, Aditya Das, Sonali Sudan, Gamini, Angelica, Mohini Tyagi, Nikhil Singhal

Singer: Umesh Singh Matka, Kushagra Dubey, Achal Grover, Mukesh Rajeshwari Singh

Asst. Producer: Rohit Takia, Neha Kumar

Casting: Uberlatin Models, Esther Jamir

Makeup: Mithlesh

Background Score & Music Arranger: Victor Dutt

About NRAI Productions

NRAI Productions owns an entertainment and lifestyle web portal http://www.cinematop10.com. It also owns a YouTube channel ‘Bollywood news movies‘. ‘My Virgin Diary‘ is produced by ‘NRAI Productions‘ which is an audio visual production house and a sister concern of NRAI School of Mass Communication. Apart from Producing movies and short films, it has recently ventured into radio production, ad films and radio jingles.

Media Contact:
Nalin Singh
info@nraismc.com
+91- 9899045628
NRAI School of Mass Communication

How to shoot terrific video on your mobile device

These days, most of us walk around with an HD video camera in our pocket.

Thanks to people’s growing appetite for mobile and video, the technology in our phones, tablets and other mobile devices gets better and better.

Marketers and other content creators are turning to mobile devices to capture behind-the-scenes glimpses of their office, industry events and trade shows, and spur-of-the-moment videos for social media.

Although mobile devices make video storytelling easier, executing a high-quality video is not as simple as whipping out your smartphone, pointing it and shooting.

So, don’t press that record button so fast. Consider these tips to create polished video content on the go:

1. Orient yourself.

Although vertical video is becoming more widely accepted (given the popularity of video messaging app, Snapchat), content that lives elsewhere will most likely have to conform to a widescreen player and horizontal orientation.

Before you start shooting your video, decide where and how you’ll use it, and then orient your video recording device accordingly.

2. Hold your shots.

As a rule, you should hold each shot for at least 10 seconds. Then, when you reach the cutting room, you’ll have enough video to play with to create a scene. You can always trim the clip, but you can’t add what you didn’t shoot.

Be careful of panning and zooming too much, as it could become jarring. Think about the way your eyes naturally view the world. You might scan a crowd, but generally your sights land on one image at a time, whether you roll your eyes or turn your head.

Finally, steady your shots. Use a tripod whenever possible. Otherwise, find another way to lock down your camera and hold it in place.

[RELATED: Join digital expert Shel Holtz for the Big 5 Social Media Boot Camp in NYC.]

3. Shoot in sequence.

Just as you write a story sequentially, make sure you shoot video in sequential order.

Let’s imagine you’re shooting video of a dog on a treadmill (because even pets have summer weight loss resolutions).

Start with a wide shot to set the scene. Without adjusting your angle (we’ll get there, just not yet), move in a little closer to get a medium shot, cropping out most of the treadmill and focusing on the dog’s body in motion.

Shy away from using the zoom feature, because that can lead to shaky video. Instead, let your feet do the walking.

Finally, get a close-up shot, perhaps filling the screen with the dog’s panting face.

You just shot one sequence. Now it’s time to adjust your angle and shoot a similar sequence. You can shoot from above, from below, from another side or from behind. Have fun with it.

4. Set the stage for interviews.

Avoid conducting interviews in front of a generic background that adds little to your overall messaging and story.

Instead, put your interview subject in a relevant environment. For example, if the interview is about the benefits of bicycling and offers safety tips, let’s see the person with a row of bicycles behind them, or suit them up in gear and put them on a bike trail. You get the picture.

Shooting interviews on a mobile device is often challenging because of the audio quality. So, get close to your interview subject. If you have another phone handy, use one to record video and the spare to capture sound in an audio file.

Before you start the interview, clap your hands together once in view of the camera. This will create a mark that you can eventually use in the edit to sync the video with the audio.

Make sure your shot is framed up nicely. The last thing you want to see is some pole or a plant growing out of someone’s head. Provide head room, and leave enough talking space for your interview subject. This is known as the „rule of thirds.”

Horizontally, one-third of the frame should appear above the person’s eye line. Another third should cover the person’s face and shoulder area. Leave the bottom third for the person’s upper body.

When shooting an interview with the person looking off screen, leave enough room (about a third of the screen) in front of the person (favoring the direction he or she is looking) to create talking space.

5. Insist on quiet on the set.

Noise—particularly irrelevant sound from the crew—can pollute an otherwise terrific shot. Although audio is often overlooked, it can really enhance and drive the video’s story.

You want to capture the cleanest possible audio, especially when it’s vital to the shot. It’s arguably never more important than when you’re conducting an interview.

Bottom line: When the camera’s rolling, hold your tongue. The camera picks up virtually everything on its microphone, and you can’t edit it out.

To connect with your audience and convert them into customers, follow the guidelines above to create high-quality, visually engaging content.

Wes Benter is a senior online community services specialist at ProfNet. A version of this article originally appeared on Beyond PR.

(Image via)

Maxtech Continues Manganese Due Diligence in Mato Grosso, Brazil, Files Regional NI 43-101

VANCOUVER, BC–(Marketwired – March 30, 2017) – Maxtech Ventures Inc. (CSE: MVT) (CSE: MVT.CN) (OTC PINK: MTEHF) (FRANKFURT: M1N) („Maxtech” or the „Company), is pleased to announce it has filed on SEDAR its initial regional National Instrument 43-101 – Standards of Disclosure for Mineral Projects („NI 43-101”) for the Brasnorte research concessions, located in the State of Mato Grosso, Brazil entitled „Hydrothermal Manganese Mineralization Rondonia / Mato Grosso, Brazil.”

The Company continues their acquisition strategy to grow with additional manganese claims. Further due diligence was necessary in this region to determine future costs of mining exploration and near term production opportunities. The NI 43-101 will assist Maxtech by identifying similar characteristics in other potential mineralized material claims throughout the region.

Summary Report Excerpt: This report has been prepared as an overview of the emerging high quality, hydrothermal manganese mineralized camp located in the western Brazilian States of Rondonia and Mato Grosso. The known mineralization strikes easterly for at least 250 km from Eastern Rondonia across the State borders into Mato Grosso. Mineralization consists primarily of hydrothermal manganese in the form of pyrolusite (MnO2). It occurs as surficial, eroded clasts and cobbles of material with assays reported to greater than 54% Mn and less weathered, primary veins of similar material. Veins have been shown to extend from surface to below 80 metres and still be open below that depth.

John Harper: The author, has worked in the region since 2006, initially conducting exploration and bulk sampling of diamond bearing kimberlites. From 2008 he has reviewed, mapped and developed numerous (~100) manganese showings, several of which were or currently are in production. Mr. Harper is an international mineral exploration geoscientist and consultant with over 30 years industry experience in base and precious metals, manganese, uranium and diamond exploration. He is a member in good standing of the Association of Professional Engineers and Geoscientists of Alberta (APEGA) and Ontario (APGO). His international experience has taken him to projects throughout North America, Brazil and Africa. For the past several years, his expertise has taken him to Brazil where he has managed comprehensive exploration programs for Meridian Mining S.E. manganese claims.

The technical information contained in this news release has been reviewed and approved by Mr. John Harper B.Sc., P.Geol, who is a Qualified Person with respect to Maxtech’s manganese project as defined under National Instrument 43-101.

About Maxtech Ventures Inc.

Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.

For additional information see the Company’s web site at http://www.maxtech-ventures.com.

Email to info@maxtech-ventures.com.

Further information about the Company is available on www.SEDAR.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this release may constitute „forward-looking statements” or „forward-looking information” (collectively „forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words „could”, „intend”, „expect”, „believe”, „will”, „projected”, „estimated”, „anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Maxtech Continues Manganese Due Diligence in Mato Grosso, Brazil, Files Regional NI 43-101

VANCOUVER, BC–(Marketwired – March 30, 2017) – Maxtech Ventures Inc. (CSE: MVT) (CSE: MVT.CN) (OTC PINK: MTEHF) (FRANKFURT: M1N) („Maxtech” or the „Company), is pleased to announce it has filed on SEDAR its initial regional National Instrument 43-101 – Standards of Disclosure for Mineral Projects („NI 43-101”) for the Brasnorte research concessions, located in the State of Mato Grosso, Brazil entitled „Hydrothermal Manganese Mineralization Rondonia / Mato Grosso, Brazil.”

The Company continues their acquisition strategy to grow with additional manganese claims. Further due diligence was necessary in this region to determine future costs of mining exploration and near term production opportunities. The NI 43-101 will assist Maxtech by identifying similar characteristics in other potential mineralized material claims throughout the region.

Summary Report Excerpt: This report has been prepared as an overview of the emerging high quality, hydrothermal manganese mineralized camp located in the western Brazilian States of Rondonia and Mato Grosso. The known mineralization strikes easterly for at least 250 km from Eastern Rondonia across the State borders into Mato Grosso. Mineralization consists primarily of hydrothermal manganese in the form of pyrolusite (MnO2). It occurs as surficial, eroded clasts and cobbles of material with assays reported to greater than 54% Mn and less weathered, primary veins of similar material. Veins have been shown to extend from surface to below 80 metres and still be open below that depth.

John Harper: The author, has worked in the region since 2006, initially conducting exploration and bulk sampling of diamond bearing kimberlites. From 2008 he has reviewed, mapped and developed numerous (~100) manganese showings, several of which were or currently are in production. Mr. Harper is an international mineral exploration geoscientist and consultant with over 30 years industry experience in base and precious metals, manganese, uranium and diamond exploration. He is a member in good standing of the Association of Professional Engineers and Geoscientists of Alberta (APEGA) and Ontario (APGO). His international experience has taken him to projects throughout North America, Brazil and Africa. For the past several years, his expertise has taken him to Brazil where he has managed comprehensive exploration programs for Meridian Mining S.E. manganese claims.

The technical information contained in this news release has been reviewed and approved by Mr. John Harper B.Sc., P.Geol, who is a Qualified Person with respect to Maxtech’s manganese project as defined under National Instrument 43-101.

About Maxtech Ventures Inc.

Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.

For additional information see the Company’s web site at http://www.maxtech-ventures.com.

Email to info@maxtech-ventures.com.

Further information about the Company is available on www.SEDAR.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this release may constitute „forward-looking statements” or „forward-looking information” (collectively „forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words „could”, „intend”, „expect”, „believe”, „will”, „projected”, „estimated”, „anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Bonterra to Acquire Strategic Trove Property as Extension of Bonterra’s Southwest Trend

March 30, 2017 / TheNewswire / Vancouver, BC – Bonterra Resources Inc. (TSX.V:BTR, US:BONXF, FSE:9BR1) („Bonterra” or the „Company„) is pleased to announce that it has entered into an option agreement (the „Agreement„) with Durango Resources Inc. (TSX.V:DGO) („Durango„), by which Bonterra can earn a 100% interest in Durango’s Trove Windfall Lake Property (the Trove Property„) located in the Urban-Barry Gold Camp district of northern Quebec.

The Trove Property is a direct extension of the south west mineralized trend that Bonterra is currently exploring on its Gladiator gold deposit and Coliseum gold property. The Company’s technical team brings extensive experience associated with the type of geology hosted by the Trove Property.

Nav Dhaliwal, President and Chief Executive Officer of Bonterra, stated, „We are pleased to have entered into this agreement with Durango on the Trove Property, and to add significant value to Bonterra’s large land portfolio in the Urban-Barry Gold Camp, noting the Trove Property’s strategic location. The Urban-Barry Camp is one of most exciting and busiest camps in Canada, and 2017 looks to exceed expectations and outpace the previous year.”

Pursuant to the Agreement, Bonterra can earn a 100% interest in the Trove Property by making the following payments and share issuances and undertaking the following exploration work:

  • -Pay $150,000 and issue 1,500,000 common shares within two business days of the date the TSX Venture Exchange accepts the transaction (the „Closing Date„);

    -On or before the first anniversary of the Closing Date, pay a further $150,000 and issue an additional 1,500,000 common shares;

    -On or before the second anniversary of the Closing Date, pay $200,000 and complete a minimum of $1,000,000 in exploration expenditures;

Upon which Bonterra will have exercised the option and full title of the Trove Property will be transferred from Durango to Bonterra;

Durango will retain a 2% net smelter returns royalty in respect of the Trove Property. Bonterra may purchase 50% of this royalty at any time for $1,000,000.

For its efforts in introducing Durango to the Company, the Company will issue as a finder’s fee to CJC Technology Inc. (Carlos Cervantes) 267,284 common shares.

Acquisition of the Trove Property and payment of the finder’s fee are subject to the acceptance of the TSX Venture Exchange.

Bonterra Resources Quick Facts:

ON BEHALF OF THE BOARD OF DIRECTORS,

Nav Dhaliwal, President & CEO

Bonterra Resources Inc.

For further information on Bonterra, contact Investor Relations

Telephone: 1 844 233 2034

Email: ir@bonterraresources.com

Website: www.bonterraresources.com

Forward-Looking Statements

This document may contain or refer to forward-looking information based on current expectations, including, but not limited to the completion of the transaction, obtaining the approval of the TSX Venture Exchange, the prospect of Bonterra achieving success in exploring the Trove Property, and the impact on Durango and Bonterra of these event, including the effect on the share prices of both Durango and Bonterra. Forward-looking information is subject to significant risks and uncertainties, as actual results may differ materially from forecasted results. Forward-looking information is provided as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances. For a detailed list of risks and uncertainties relating to Durango, please refer to its prospectus filed on its SEDAR profile at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

US Sports Camps’ Camp All-Star Announces Special Weekend Activities

News Image

This summer Camp All-Star is offering two additional special activities for campers to enjoy on selected Sundays.

Past News Releases

RSS

Before the summer, Camp All-Star campers, along with their parents, customize their daily programs on the All-Star Maine activities selection form. Kids can participate in a skill-appropriate major sport for up to 2 periods per day. They then select from the list of Major Sports and All-Star Maine Skills to complete their activity schedule.

This summer, however, Camp All-Star is offering two additional special activities for campers to enjoy on selected Sundays. Ripe with excitement, campers have the opportunity to play “the large game” in the wide open ocean, experiencing the challenge of catching magnificent and elusive deep sea fish. An experience appetizing enough for any camper with a love or interest in the sport of fishing. If that is not exciting enough, campers can choose to ride over rushing whitewater, feeling sprays of freshwater on their faces while navigating through whirlpools of fun. Whitewater rafting is an incredible opportunity for campers to experience the thrill and adrenaline that comes from riding rough waters.

Campers who wish to partake in these activities must choose the sport that they find most exciting. White Water Rafting or Deep Sea Fishing are offered on July 9th and July 23rd, on which campers must choose one of the sports. Each trip is $200 and campers must already be at the camp to participate.

Campers, parents, and coaches interested in Camp All-Star this summer can visit http://www.ussportscamps.com/multisport/camp-all-star/maine or call 1-800-645-3226.

About US Sports Camps

US Sports Camps (USSC), headquartered in San Rafael, California, is America’s largest sports camp network and the licensed operator of NIKE Sports Camps. The company has offered summer camps since 1975 with the same mission that defines it today: to shape a lifelong enjoyment of athletics through high quality sports education and skill enhancement.

Share article on social media or email:

Myths and Mountains Identify Three New Trends in Travel to Galapagos

Birds of Galapagos

„”Flying in a small plane over the Galapagos Islands provides a birds-eye view of these volcanic formations,” Allie Alimario, Myths and Mountains.

Myths & Mountains Vice President and Galapagos specialist, Allie Almario, just returned from her 14th scouting trip to the Galapagos where she discovered three growing trends.

1. Leaving ships behind, many are choosing to spend time on land in new luxury lodging including the new Galapagos Safari Camp on Santa Cruz Island.

2. Secondly, six-seater prop planes offer “air taxi” service for island hoppers. Galapagos By Air gives a bird’s-eye view of jaw-dropping volcanic islands and islets, as well as being a time-saver.

3. The third trend is evolving around the concept of “more time on less islands,” allowing visitors to explore an island more in-depth. More travelers are embracing the idea that “less is more.” By concentrating on a few islands and spending days on them rather than hours, visitors enjoy an in-depth, leisurely experience in the Galapagos. On longer stays, visitors stay overnight at a hotel on one of the four inhabited islands (Santa Cruz, San Cristobal, Isabela, and Floreana) and explore nearby islands on day trips. There will even be time for a half-day kayak trip!

As a leading tour operator, Myths and Mountains have been taking travelers to the Galapagos for more than 20 years. They stay ahead of trends and curate the most ideal itineraries possible while maintaining strict standards for sustainability. Long-time relationships with local providers and wildlife conservationists assure guests a personalized and immersive experience.

For more information on Myths and Mountains tours, please visit http://www.mythsandmountains.com. You can also read Myths and Mountains’ blog and follow them on Facebook, Twitter, Google +, Instagram and other networks.

###

About Myths and Mountains

Veteran adventurer Dr. Antonia Neubauer founded Myths and Mountains in 1988 to foster intimate cross-cultural experiences and offer tours designed to take travelers to the very heart of the places they visit. The company’s mission to provide handcrafted, experiential journeys has created a solid place for Myths and Mountains in the adventure travel industry. They were named Trusted Travel Experts on the 2017 Wendy Perrin WOW List. Allie Almario is the WOW expert for Ecuador and the Galapagos, while Dr. Neubauer is the WOW expert for Bhutan, Nepal and now Myanmar. Dr. Neubauer has also been Condé Nast Traveler’s Nepal and Bhutan Top Travel Specialist since 2011.

Achievements: “Ultimate Adventure Outfitters From Around the Globe” – Travel + Leisure Magazine, 2010; “50 Tours of a Lifetime” – National Geographic Traveler, 2013 and 2015. Myths and Mountains was presented the 2015 Legacy in Travel Philanthropy Award from Tourism Cares.

Share article on social media or email:

Pune to be Part of the Global Azure Boot Camp 2017

Fintech Thought Leaders are proud to be organizing the Central Pune event as part of the Global Azure Boot Camp. This event is planned and targeted for practitioners working in the Financial Services space or those aspiring to work in this domain.

Pune, India, March 30, 2017 –(PR.com)– Global Azure Boot Camp 2017 is a community driven event supported by Microsoft. On 22nd April 2017 thousands of technology enthusiasts will converge at local events being organized in over 200 locations all over the world. Global Azure Bootcamp 2017 is lined up to be the biggest bootcamp yet – appropriate for the fifth year anniversary. Currently it is estimated that well over 10,000 attendees world-wide will show up for Global Azure 2017.

Fintech Thought Leaders are proud to be organizing the Central Pune event as part of the Global Azure Boot Camp. This event is planned and targeted for practitioners working in the Financial Services space or those aspiring to work in this domain. They plan to have about 50 participants in this event. This will be a half day event, starting in the afternoon with sessions focused on Azure cloud and the challenges faced in the financial services domain. Post the speaker sessions there will be music, drinks, nibbles and light dinner in the evening over a networking session.

The Pune event is unique in that it is focussed on practitioners working in the Financial Services space and the talk session is followed on by a networking event over music dedicated to George Michael.

This is an opportunity to spend an afternoon getting into the nitty gritties of Azure Cloud and later network over good beer, eating good food, listening to good music on an open air terrace on a hot Indian summer evening. The music will be a dedication to George Michael. Speaking about the connect between music and software development, Nilesh Kadam, member of the organizing committee said, “So many of the best minds I have met in computing have a love for music. I believe this is something to do with being able to see beauty in complex numerical systems. George Michael has been an inspiration for me and I wanted to dedicate this evening to him.”

Creating music and software are both collaborative and individualistic undertakings. Musicians are generally technically engaged. The instruments themselves often interface with other devices (amps, mixers, mutes) to achieve different sounds. Composers often deal with an array of technologies to get their music written, performed and produced. Music is an abstract medium – the printed note requires interpretation and execution. Like the written line of code, there is often much more than meets the eye. Guitar players in particular make great programmers. Instrumentalists have to zoom in to work with very repetitive technical details, and so become very focused – like a guitar player practicing a piece of music at a slow speed. But, the best programmers are able to then zoom out and see the big picture, and where their coding fits into the whole project, much like an artist has to step back from a painting and see the whole of it, or an instrumentalist has to produce something that communicates a complete work, not just the scales and technical aspects of it. There are rhythms and cadences of algorithmic flow.

Sponsorship opportunities – This is a community event and sponsors are welcome to reach out to help support this community in organizing the event. This is a great opportunity to connect with Cloud enthusiasts and practitioners and having your logo displayed on what probably is the biggest distributed event in the world. You will be supporting Pune organize the coolest of all the events across the globe.

FinTech Thought Leaders (FTTL) is a community of software practitioners working in the Finance domain. FTTL was formed by individuals from the FinTech space, who felt that there was a need for a platform for practitioners from this industry to get together and share their experiences and talk about the innovative work they are doing. The platform will enable the practitioners in this space understand the common challenges the industry faces, drive innovation and nurture leaders who are willing to think out of the box.

As part of this initiative FinTech Thought Leaders had its maiden event – AgileFest2016 an event where participants got to meet and hear from leading industry practitioners on how software craftsmanship is changing with the adoption of the Agile methodology for faster delivery. There were sessions on Finance, Regulation and software craftsmanship. The event was attended by over 200 participants from over 30 organizations, including Barclays, Citibank, Master Card, Credit Suisse, Mastek, Oracle and a host of small and medium start-ups based in Pune and Mumbai.

The community has over 300 active members besides an executive team of 20 practitioners from the industry. To find out more about FinTech Thought Leaders and about the Pune Global Azure BootCamp please visit www.azure17.com